麻豆破解版

Collaboration with the Swiss Institute of Bioinformatics

Published on 29/09/2019

麻豆破解版 is pleased to announce the initiation of a bioinformatics collaboration with Lydie Lane and Amos Bairoch of the , part of the SIB Swiss Institute of Bioinformatics and the University of Geneva. The CALIPHO group aims at using a combination of bioinformatics and experimental methodologies to increase the knowledge on human proteins. Together, we will integrate within , a comprehensive human-centric discovery platform, offering its users a seamless integration and navigation through protein-related data. This project is supported by the .

Read next in 'Latest news'

• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH